Characterisation of heterozygous PMS2 variants in French patients with Lynch syndrome

被引:12
|
作者
Wang, Qing [1 ]
Leclerc, Julie [2 ,3 ]
Bougeard, Gaelle [4 ,5 ]
Olschwang, Sylviane [6 ]
Vasseur, Stephanie [4 ,5 ]
Cassinari, Kevin [4 ,5 ]
Boidin, Denis [7 ]
Lefol, Cedrick [1 ]
Naibo, Pierre [1 ]
Frebourg, Thierry [4 ,5 ]
Buisine, Marie Pierre [2 ,3 ]
Baert-Desurmont, Stephanie [4 ,5 ]
机构
[1] Ctr Leon Berard, Lab Constitut Genet Frequent Canc, HCL CLB, F-69008 Lyon, France
[2] Lille Univ, JPA Res Ctr, INSERM UMR S 1172, Lille, France
[3] Lille Univ Hosp, Dept Biochem & Mol Biol, Lille, France
[4] Rouen Univ Hosp, Dept Genet, Rouen, France
[5] Normandy Ctr Genom & Personalized Med, UNIROUEN, Rouen, France
[6] Aix Marseille Univ, Hop Europeen & Grp Ramsay Gen Sante, Hop Clairval, Dept Genet Med,INSERM GMGF UMR 1251, Marseille, France
[7] Lille Univ Hosp, Dept Biochem & Mol Biol, Lille, France
关键词
cancer predisposition; Lynch syndrome; germline variant; MMR deficiency; PMS2; MISMATCH REPAIR; MUTATIONS; GUIDELINES; HNPCC;
D O I
10.1136/jmedgenet-2019-106256
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Heterozygous germlinePMS2variants are responsible for about 5% of Lynch syndrome (LS) but their prevalence is most likely underestimated because of complicated routine screening caused by highly homologous pseudogenes. Consequently, there is limited knowledge on the implication of thePMS2gene in LS. Methods We report 200PMS2heterozygous variants identified in 195 French patients, including 112 unique variants classified as class-3/4/5. Results Genomic rearrangements account for 18% of alterations. The c.137G>T variant was observed in 18% of the patients, but a founder effect could not be clearly identified by haplotype analysis. Among class-4/5 variant carriers, the median age at first tumour onset was 49 years with a predominance of colorectal (80%) and endometrial (8.1%) cancers. Seven patients developed colorectal cancers before the age of 30 with the youngest at the age of 21. Only 6.2% of class-4/5 carriers had a family history fulfilling Amsterdam I/II criteria among patients with available data. Tumours fromPMS2variant carriers exhibited microsatellite instability (96%) and loss of PMS2 expression (76%), confirming the high predictive value of somatic analysis. Conclusion Our results provide further insight into the role of thePMS2gene in LS. WhilePMS2variants are mostly detected in families not fulfilling Amsterdam criteria, which supports their lower penetrance, they can nevertheless cause early-onset cancers, highlighting the variability of their penetrance.
引用
收藏
页码:487 / 499
页数:13
相关论文
共 50 条
  • [21] PMS2 Pathogenic Variant in Lynch Syndrome- Associated Colorectal Cancer with Polyps
    Poaty, Henriette
    Bouya, Lauria Batamba
    Lumaka, Aime
    Mongo-Onkouo, Arnaud
    Gassaye, Deby
    GLOBAL MEDICAL GENETICS, 2023, 10 (01): : 1 - 5
  • [22] MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer
    Roberts, Maegan E.
    Jackson, Sarah A.
    Susswein, Lisa R.
    Zeinomar, Nur
    Ma, Xinran
    Marshall, Megan L.
    Stettner, Amy R.
    Milewski, Becky
    Xu, Zhixiong
    Solomon, Benjamin D.
    Terry, Mary Beth
    Hruska, Kathleen S.
    Klein, Rachel T.
    Chung, Wendy K.
    GENETICS IN MEDICINE, 2018, 20 (10) : 1167 - 1174
  • [23] Characterization of colorectal cancer (CRC) in Lynch syndrome (LS) patients with MSH6 or PMS2 mutations
    Lee, Jean Kyung
    Shia, Jinru
    Rau-Murthy, Rohini
    Corines, Marina
    Salo-Mullen, Erin E.
    Markowitz, Arnold
    Robson, Mark E.
    Offit, Kenneth
    Guillem, Jose G.
    Saltz, Leonard
    Stadler, Zsofia Kinga
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] COLORECTAL CANCER IN MSH6 AND PMS2 LYNCH SYNDROME PATIENTS: CLINICAL PHENOTYPE IN A US POPULATION
    Guivatchian, Tannaz
    Rifkin, Samara
    Greve, Veronica
    Martinez, Julia
    Koeppe, Erika
    Stoffel, Elena M.
    GASTROENTEROLOGY, 2023, 164 (06) : S775 - S775
  • [25] Quantification of Sequence Exchange Events between PMS2 and PMS2CL Provides a Basis for Improved Mutation Scanning of Lynch Syndrome Patients
    van der Klift, Heleen M.
    Tops, Carli M. J.
    Bik, Elsa C.
    Boogaard, Merel W.
    Borgstein, Anne-Marijke
    Hansson, Kerstin B. M.
    Ausems, Margreet G. E. M.
    Garcia, Encarna Gomez
    Green, Andrew
    Hes, Frederik J.
    Izatt, Louise
    van Hest, Liselotte P.
    Alonso, Angel M.
    Vriends, Annette H. J. T.
    Wagner, Anja
    van Zelst-Stams, Wendy A. G.
    Vasen, Hans F. A.
    Morreau, Hans
    Devilee, Peter
    Wijnen, Juul T.
    HUMAN MUTATION, 2010, 31 (05) : 578 - 587
  • [26] Prevalence of mutations in MSH6, PMS1 and PMS2 gene in Brazilian families with Lynch syndrome
    Silva, Felipe C.
    Torrezan, Giovana T.
    Lisboa, Bianca G.
    Santos, Erika M.
    Gomy, Israel
    Rossi, Benedito M.
    Ferreira, Fabio O.
    Carraro, Dirce M.
    CANCER RESEARCH, 2012, 72
  • [27] In silico splicing analysis of the PMS2 gene: exploring alternative molecular mechanisms in PMS2-associated Lynch syndrome
    Munteanu, Catalin Vasile
    Marian, Catalin
    Chirita-Emandi, Adela
    Puiu, Maria
    Trifa, Adrian Pavel
    BMC GENOMIC DATA, 2024, 25 (01):
  • [28] A case of early onset rectal cancer of Lynch syndrome with a novel deleterious PMS2 mutation
    Nomura, Sachio
    Fujimoto, Yoshiya
    Yamamoto, Noriko
    Sato, Yuri
    Ashihara, Yuumi
    Kita, Mizuho
    Yamaguchi, Junya
    Ishikawa, Yuichi
    Ueno, Masashi
    Arai, Masami
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (10) : 987 - 992
  • [29] A Case of Concomitant Duodenal and Colonic Primary Adenocarcinoma in a Patient With PMS2 Deficient Lynch Syndrome (
    Roy, Divya
    He, Harry
    Patel, Zinal
    Manvar, Amar
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S2143 - S2144
  • [30] In vitro data suggest a role for PMS2 Kozak sequence mutations in Lynch syndrome risk
    Matoy, Evanjalina J.
    Plowman, Jocelyn N.
    Watson, Cynthia J.
    Belshan, Michael A.
    Blue, Elizabeth E.
    Huff, Chad D.
    Stessman, Holly A. F.
    HUMAN GENETICS AND GENOMICS ADVANCES, 2024, 5 (03):